Assess and manage vulvodynia and chronic vulvar pain

In one line

Vulvodynia is vulvar pain of at least three months' duration with no clear identifiable cause — a diagnosis reached only after a specific disorder has been excluded — and it is managed not with a single drug but with a multimodal, multidisciplinary plan built around a credible biopsychosocial explanation, because no monotherapy reliably beats placebo.

The groundwork — the anatomy of the vestibule, the differential of vulvar pain and the basics of provoked vestibulodynia — is the Intermediate vestibulitis chapter (FCOG Intermediate, General gynaecology → "Vestibulitis"); this builds on it. The consultant task here is the harder one: to separate true vulvodynia from the long list of conditions that mimic it, to construct a defensible formulation when the evidence base is thin, and to argue treatment choices from trials that are mostly small, mostly negative against placebo, and honest about it.

Mechanism & pathophysiology

The single most important conceptual move, fixed by the 2015 ISSVD/ISSWSH/IPPS consensus terminology, is the split between vulvar pain caused by a specific disorder and vulvodynia itself. Vulvar pain caused by a specific disorder has a name and a treatment: candidiasis, herpes, lichen sclerosus or lichen planus, a fissure, a fixed drug eruption, a pudendal neuralgia, an oestrogen-deficient atrophic vestibule, a desquamative inflammatory vaginitis. Vulvodynia is what is left when all of those have been excluded — vulvar pain of ≥3 months with no clear identifiable cause. It is therefore, by definition, a diagnosis of exclusion, and the commonest reason a "refractory vulvodynia" fails treatment is that it was never vulvodynia: a low-grade candidal vestibulitis, an under-recognised lichen sclerosus, or a vaginal atrophy was driving the pain all along.

The 2015 framework also gives the descriptors that organise the rest of the reasoning. Pain is classified by site (localised — most often the vestibule, provoked vestibulodynia, formerly "vulvar vestibulitis"; generalised — the whole vulva; or mixed), by provocation (provoked by contact/penetration, spontaneous, or mixed), by onset (primary, present from the first attempt at penetration or tampon use, versus secondary, acquired after a period of pain-free function), and by temporal pattern (intermittent, persistent, constant, immediate, delayed). The terminology deliberately appends a list of associated factors rather than causes — comorbid pain conditions, musculoskeletal and pelvic-floor dysfunction, inflammatory and infectious triggers, neurological mechanisms, hormonal factors, structural and psychosocial contributors — because the honest position is that vulvodynia is a final common pathway, not one disease.

The mechanistic core a consultant must hold is that vulvodynia behaves like a chronic neuropathic and central-sensitisation pain syndrome localised to the vulva, not like ongoing tissue injury. Three layers stack:

• Peripheral sensitisation. Biopsy and quantitative-sensory-testing studies of provoked vestibulodynia show increased density of vestibular nociceptive C-fibre and A-delta free nerve endings — a neural hyperplasia in the vestibular mucosa — together with a local low-grade inflammatory and immune signature (increased mast-cell numbers and degranulation, raised pro-inflammatory cytokines, and upregulated nociceptor transducers such as TRPV1) in a vestibule that often looks entirely normal. The embryology matters here: the vestibule is endodermal in origin, distinct from the ectodermal vulvar skin lateral to Hart's line, which is part of why pain localises to this precise zone. The result is allodynia — light touch (a cotton swab, a tampon, penetration) is read as pain — with the mucosa intact. This is why "there is nothing to see" never excludes the diagnosis.
• Central sensitisation. As in other chronic pain, repeated nociceptive input amplifies dorsal-horn and central processing, lowers pain thresholds at sites remote from the vulva, and explains the strong overlap with other central-sensitivity syndromes — irritable bowel, fibromyalgia, interstitial cystitis/bladder pain syndrome, temporomandibular disorder, chronic fatigue and migraine. A patient with several of these has a centrally sensitised nervous system, and that prediction shapes both the explanation you give and the drugs you reach for.
• Pelvic-floor hypertonicity. Pain provokes a protective reflex tightening of the levator ani; the hypertonic, tender pelvic floor then becomes an independent pain generator and a barrier to penetration, closing a self-sustaining loop of pain → guarding → more pain. This is why pelvic-floor physiotherapy is mechanistic treatment, not adjunct comfort.

Hormonal and psychosexual layers sit on top. A subset of provoked vestibulodynia is associated with combined hormonal contraception: suppressed ovarian oestradiol and testosterone plus a raised sex-hormone-binding globulin lower free androgen and oestrogen at the vestibule, thinning the epithelium and, on the prevailing hypothesis, sensitising the nociceptors — a state that can be partly reversed by stopping the pill and applying topical oestrogen/testosterone. A further subset overlaps the genitourinary syndrome of menopause. Both blur into "specific disorder" territory and both are treatable, which is why a hormonal history and an oestrogen assessment of the vestibule are part of the work-up rather than an afterthought. There is also a heritable and immunogenetic thread — familial clustering, an association with a history of recurrent candidiasis, and polymorphisms in inflammatory genes (for example in the interleukin-1 receptor antagonist and mannose-binding lectin pathways) have been reported — consistent with a primed, hyper-reactive local immune response in predisposed women, though none of this is yet a clinical test. The psychosexual layer — anxiety, hypervigilance, catastrophising, fear-avoidance, relationship distress, and a history of sexual trauma in some women — is not a competing "psychological cause" to be set against the "physical" one; it is a modulator of the same nociceptive system, descending facilitation and arousal amplifying the very spinal processing that peripheral sensitisation feeds, and treating it (CBT, sex therapy) measurably moves pain. Holding the biopsychosocial model as one mechanism, rather than a polite list, is what separates a consultant answer from a registrar's.

Assessment

The assessment has one job before all others: to decide whether this is vulvodynia or vulvar pain caused by something specific and treatable. Everything below serves that exclusion, then the biopsychosocial formulation.

• Structured history. Characterise the pain in the 2015 descriptors — localised or generalised, provoked or spontaneous, primary or secondary, and its temporal pattern — because the descriptor predicts the management (provoked vestibulodynia is the physiotherapy-and-topical-and-CBT phenotype; generalised spontaneous vulvodynia is the neuromodulator-led, pain-clinic phenotype). Ask specifically about dyspareunia (entry versus deep), tampon use, the relationship to the menstrual cycle and to contraception, and the impact on the relationship and on mood.
• Screen for the central-sensitivity comorbidities explicitly — IBS, bladder pain syndrome, fibromyalgia, migraine, TMJ, chronic fatigue. Their presence both supports the diagnosis and steers you towards centrally-acting drugs.
• Drug and hormonal history. Combined hormonal contraception, aromatase inhibitors, and the menopausal transition all produce a hypo-oestrogenic vestibule that mimics or causes provoked pain.
• Psychosocial history, sensitively taken: anxiety and depression screening, fear-avoidance and catastrophising, relationship dynamics, and — asked safely and without assuming — any history of sexual violence, which in the South African setting is common enough that it must be enquired about, with a clear pathway to support if disclosed.
• Inspection to exclude a dermatosis or infection: the architecture of lichen sclerosus (pallor, atrophy, loss of architecture, fissuring) or lichen planus (Wickham striae, erosions, a desquamative vaginitis), fissures, ulcers, erythema, atrophic change. A vulva that looks abnormal points away from vulvodynia and towards a specific disorder.
• The cotton-swab (Q-tip) test, the single most useful examination manoeuvre. Map light-touch allodynia systematically around the vestibule (a clock-face), the labia, the perineum and the interlabial sulci. In classic provoked vestibulodynia the allodynia is sharply localised to the vestibule, often maximal posteriorly (5 and 7 o'clock), with normal sensation on the labia majora — a positive, reproducible map on an otherwise normal-looking vestibule is the clinical signature.
• Pelvic-floor assessment. Palpate the levator ani and obturator internus for resting hypertonicity, tenderness and trigger points, and assess the patient's ability to relax and contract — the hypertonic, tender pelvic floor is both diagnostic and a treatment target, and missing it under-treats the patient.
• Exclude infection and treat the treatable. A vaginal pH, microscopy and culture (including for candida — recurrent or low-grade candidiasis is a classic mimic), and a low threshold to swab for herpes if the history fits. Vulvar biopsy is not routine for vulvodynia (the point is that there is nothing to biopsy); reserve it for a visible lesion, suspected dermatosis, or anything atypical or non-healing — never to "confirm" vulvodynia, which has no histological diagnosis.
• Assess for a neuralgia. A unilateral, dermatomal, burning pain in the pudendal distribution, worse on sitting and relieved by standing or sitting on a toilet seat, suggests pudendal neuralgia rather than vulvodynia — a different entity with a different work-up (and one of the "specific disorders" the terminology carves out).

Two further distinctions from the history carry prognostic weight. Primary versus secondary onset matters: primary provoked vestibulodynia (pain from the very first attempt at penetration or tampon use) tends to be the more refractory phenotype with a stronger constitutional/immunogenetic flavour, whereas secondary disease (acquired after pain-free function, often after an infection, a dermatosis or a hormonal change) more often has an identifiable, reversible trigger to chase. And the provoked–spontaneous axis sorts the treatment lane before any drug is chosen: localised provoked vestibulodynia is the physiotherapy-topical-CBT-and-(rarely)-surgery phenotype, while generalised spontaneous vulvodynia behaves like a neuropathic pain syndrome and is led by oral neuromodulators and a pain service, with surgery offering nothing.

From this the consultant builds a biopsychosocial formulation rather than a label: which peripheral, central, musculoskeletal, hormonal and psychosexual factors are operating in this woman, weighted, because the formulation is what the multimodal plan is built from. Two women with "provoked vestibulodynia" — one with a hypertonic pelvic floor and a contraceptive-related hypo-oestrogenic vestibule, one with generalised central sensitisation, severe catastrophising and three comorbid pain syndromes — need genuinely different first moves, and the formulation is what tells them apart.

Management

Organise it immediate → ongoing → long-term, but the governing principle is set at the start: there is no reliable monotherapy, the placebo response in vulvodynia trials is large, and the gains come from a multimodal, multidisciplinary plan delivered patiently against a thin evidence base. The single most important early intervention is not a drug — it is a credible explanation and the removal of harm.

Immediate — explanation, vulvar care, and stop doing damage.

• A believable diagnosis and a biopsychosocial explanation. Many of these women have been told the pain is "in their head", have been mismanaged with repeated antifungals, or have been examined dismissively. Naming the condition, validating it as a real neuropathic pain syndrome, and explaining the pain → guarding → pain loop is itself therapeutic and is the foundation everything else is built on. Written or web-based information consolidates it.
• Vulvar care / hygiene de-escalation. Stop the irritants the patient has often layered on in desperation: scented soaps and wipes, antifungal and antiseptic creams, panty liners, tight synthetic clothing, over-washing. Substitute an emollient soap substitute and a bland emollient, and a non-irritant lubricant for intercourse. This removes a contact-dermatitis component that frequently masquerades as refractory vulvodynia.
• Treat the treatable now. Eradicate proven candidiasis, treat a dermatosis, and address a hypo-oestrogenic vestibule — a trial of topical vestibular oestrogen (± topical testosterone in selected combined-contraceptive-related cases) or stopping/switching the combined hormonal contraceptive where it is implicated. If a "specific disorder" surfaces here, the diagnosis was not vulvodynia and the pathway changes.

Ongoing — the multimodal core, layered to the formulation.

• Pelvic-floor physiotherapy is first-line, mechanistic treatment for the hypertonic-floor phenotype: down-training the overactive levator ani, manual therapy and trigger-point release, biofeedback, and graded vaginal trainers/dilators to desensitise and restore function. In a hypertonic floor it does more than any tablet, and it directly breaks the guarding loop.
• Topical agents. Topical local anaesthetic (lidocaine 2% gel or 5% ointment) for symptomatic relief and to enable physiotherapy, penetration and dilator use — used before provocation or, in some protocols, overnight. Be honest that the controlled evidence is weak (below). Topical hormonal therapy (oestrogen ± testosterone) where the vestibule is hypo-oestrogenic. Avoid topical steroids and the empirical antifungal merry-go-round unless there is a dermatosis or proven infection to treat.
• Neuromodulators for the centrally-driven, generalised or spontaneous phenotype and for provoked disease that has not responded to topical-plus-physiotherapy. Amitriptyline is the conventional first oral agent (start 10 mg nocte, titrate to effect, commonly to 25–75 mg, occasionally higher), counselling on anticholinergic and sedative effects, the slow onset, and that it is being used for its neuromodulatory (not antidepressant) effect. Gabapentinoids (gabapentin titrated upward; pregabalin as an alternative, with a clear note on dependence/misuse potential and on titration and withdrawal) are the usual second choice or an add-on. Duloxetine is a reasonable option where there is comorbid depression or a wider central pain picture. Set expectations explicitly: these are tried, given an adequate dose and duration, and stopped if they do not help — there is no agent that works for everyone, and the trial data are modest.
• Psychological therapy and sex therapy. Cognitive behavioural therapy (targeting catastrophising, fear-avoidance and hypervigilance) and psychosexual/sex therapy (for the couple, for avoidance, for the sexual-function consequences) are core treatment, not optional extras — they move pain and function in trials, and a plan that omits them is incomplete.
• Manage the comorbid central-sensitivity conditions in parallel — treating the IBS, the bladder pain syndrome, the migraine, the mood disorder — because they share a mechanism and feed the vulvar pain.

Long-term — escalation, surgery in the right patient, and realistic expectations.

• Refractory disease earns referral to a multidisciplinary vulval pain or pelvic pain service: a gynaecologist, a specialist pelvic-floor physiotherapist, a psychologist/psychosexual therapist and a pain physician, with adjuncts such as botulinum toxin to the pelvic floor, nerve blocks for a confirmed neuralgia, and management of pudendal neuralgia along its own pathway.
• Vestibulectomy has a defined, narrow place: refractory, well-localised provoked vestibulodynia in a woman whose pain is reproducibly mapped to the vestibule and who has failed adequate conservative treatment. In carefully selected patients it produces the largest pain reductions in the trial literature, but it is irreversible surgery, it does nothing for generalised or spontaneous vulvodynia, and patient selection (localised provoked disease, realistic expectations, addressed pelvic-floor and psychosexual factors) is everything. It is the last step, not a shortcut around the conservative ladder.
• Set the trajectory honestly. Persistent vulvar pain is difficult to treat, rapid resolution is unusual even with appropriate therapy, and the realistic goal is meaningful improvement in pain and function over months — framed as a chronic-pain rehabilitation, not a cure to be expected by the next visit.

The South African reality. The drugs are available and cheap — amitriptyline and gabapentin are on the formulary, topical lignocaine is accessible — so the pharmacological backbone is deliverable at district and regional level. The scarce resources are exactly the ones that matter most: specialist pelvic-floor physiotherapists, clinical psychologists and psychosexual therapists are concentrated at a few tertiary centres, and most public-sector patients will not easily reach them. The defensible plan therefore front-loads what can be delivered everywhere — the explanation, vulvar care, dilators with written instructions, a topical anaesthetic, and an oral neuromodulator with proper titration — and reserves tertiary referral (multidisciplinary clinic, vestibulectomy) for genuinely refractory, well-characterised disease, while being explicit about which parts of the international "multidisciplinary" ideal the patient in front of you will actually access. Naming that gap, rather than reciting an unreachable pathway, is the honest answer.

Guidelines compared

The bodies agree more than they diverge: all endorse the 2015 terminology, an individualised biopsychosocial formulation, a multimodal multidisciplinary plan, and surgery confined to refractory localised provoked vestibulodynia. The genuine points of difference are matters of emphasis and candour. The 2024 BASHH/BSSVD guideline is the most current and the most useful precisely because it is the most honest about the evidence — it grades most vulvodynia recommendations at the lower levels (2,C to 2,D), states plainly that "there is a lack of high-quality available evidence for many vulval conditions" and that "there seems to be a strong placebo effect associated with treatments for vulval pain", and notes that a recent meta-analysis has not confirmed a benefit of amitriptyline for unprovoked vulvodynia — a striking caveat against the drug most often prescribed first. ACOG 673, while older, sets the same tone of measured expectations. The South African layer adds nothing to the what but everything to the deliverable — the access gap, not a different recommendation.

The evidence & the controversy

The defining feature of the vulvodynia evidence base, and the thing a Final candidate must be able to say out loud, is that almost nothing reliably beats placebo in a controlled trial, and the placebo response is huge. This is not a gap to paper over with confident algorithms; it is the central fact, and a candidate who states it — and explains how to practise sensibly because of it — is reasoning at the right level.

The keystone is Foster's 2010 randomised trial of the two most commonly used pharmacological treatments. Oral desipramine and topical lidocaine, alone or in combination, failed to reduce pain more than placebo — and the numbers are the lesson: tampon-test pain fell 33% in the placebo–placebo arm, 20% with lidocaine, 24% with desipramine and 36% with the combination, with no significant difference for either active drug (desipramine P=.37, lidocaine P=.21). A placebo cream-and-tablet produced a third less pain. The authors concluded that placebo or placebo-independent effects drive the substantial improvement seen across all arms. That single result reframes the whole topic: the large non-specific improvement most clinicians attribute to "the amitriptyline" or "the lidocaine" may largely be regression to the mean, the natural history of a fluctuating condition, and the therapeutic effect of being believed, examined and given a credible plan — which is itself a reason to invest heavily in the explanation and the multimodal framework rather than in faith in any one tablet.

The gabapentin story tells the same cautionary tale with a twist. The multicentre crossover trial reported by Bachmann and Brown found that extended-release gabapentin did not improve the primary pain outcome (the tampon test) overall, yet did improve sexual function on the Female Sexual Function Index (adjusted mean difference 1.3; 95% CI 0.4–2.2; P=.008), with the pain benefit concentrated in the subgroup with higher pelvic-muscle pain on examination. The defensible reading is not "gabapentin works" or "gabapentin fails" but the more useful clinical inference: a centrally-acting agent may help a selected phenotype (the woman with a hypertonic, tender pelvic floor and central features), which is exactly why the formulation-driven, layered approach beats prescribing the same drug to everyone.

Against that pharmacological pessimism sits the more durable signal from the Bergeron randomised programme, which compared group CBT, surface-EMG biofeedback and vestibulectomy for provoked vestibulodynia. All three improved pain; vestibulectomy gave roughly twice the pain reduction of the behavioural arms and the gains were largely maintained at 2.5 years — but the surgical superiority must be stated with its caveats: seven women randomised to surgery declined it, the comparison is therefore biased toward the operated, and higher pretreatment pain and a fear of sexuality ("erotophobia") predicted worse surgical outcomes. The mature reading is that vestibulectomy can be the most effective option in carefully selected, well-localised, refractory provoked vestibulodynia, while behavioural and physiotherapy approaches help meaningfully and carry no surgical risk — so surgery sits at the end of the ladder, after selection has been done properly, not as a reflex for "treatment failure".

The honest controversy, then, is methodological as much as clinical. Trials are small, heterogeneous in how they define and measure pain, plagued by enormous placebo responses, and frequently negative — so guideline recommendations rest largely on level 2,C–2,D evidence and expert consensus, and the recent failure of meta-analysis to confirm amitriptyline's benefit should make any dogmatic first-line claim uncomfortable. There is also a live, lower-key controversy worth weighing rather than asserting: the steady creep of marketed interventions ahead of their evidence — fractional CO₂ and other vaginal/vestibular lasers, platelet-rich plasma, and an expanding menu of injectables — which have generated enthusiasm and private-sector uptake well in excess of the controlled data, and which a consultant should present as unproven and potentially harmful-to-the-purse rather than endorse. The defensible stance across the whole field is the same one the placebo data force on you: a strong therapeutic alliance, a multimodal plan, realistic timelines, and a sceptical eye on any single intervention — especially an expensive or irreversible one — that claims to be the answer.

Landmark trials & key evidence

The arithmetic worth carrying from Foster is uncomfortable and instructive: if a placebo cream-and-tablet reduces tampon-test pain by 33% and the best active combination reaches only 36%, the drug-attributable effect over placebo is on the order of a few percentage points and statistically indistinguishable from zero — so the honest message to a patient starting a topical anaesthetic or a tricyclic is that much of any improvement she feels may be non-specific, which is an argument for the cheap, low-harm, multimodal plan and against escalating to expensive or irreversible interventions on the strength of an early "response".

Exam traps & red flags

• Calling it vulvodynia before excluding a specific disorder. Vulvodynia is a diagnosis of exclusion; a missed lichen sclerosus, low-grade candidiasis, atrophic/hypo-oestrogenic vestibule, herpes or pudendal neuralgia is the commonest reason "vulvodynia" fails to respond — because it was never vulvodynia.
• "There is nothing to see, so there is nothing wrong." A normal-looking vestibule with reproducible cotton-swab allodynia is the classic finding in provoked vestibulodynia; a normal examination supports, rather than refutes, the diagnosis.
• Biopsying to confirm vulvodynia. There is no diagnostic histology; biopsy is for a visible lesion, a suspected dermatosis or an atypical/non-healing area — not to "prove" vulvodynia.
• Treating it as a single drug problem. No monotherapy reliably beats placebo; omitting pelvic-floor physiotherapy and psychological/psychosexual therapy from the plan under-treats the condition and ignores the trial data.
• Forgetting the pelvic floor. Missing a hypertonic, tender levator ani leaves the central perpetuating mechanism untreated and the topical/oral treatments under-powered.
• Promising a quick cure. Persistent vulvar pain is slow to improve even with correct treatment; over-promising erodes the therapeutic alliance that does much of the work.
• Reflex vestibulectomy for "treatment failure". Surgery helps only refractory, well-localised provoked vestibulodynia in a properly selected patient; it does nothing for generalised or spontaneous vulvodynia, and poor selection (high pretreatment pain, unaddressed psychosexual factors) predicts a poor result.
• Over-claiming amitriptyline (or any drug) as proven first-line. A recent meta-analysis has not confirmed amitriptyline's benefit; presenting it as established efficacy, rather than a reasonable empirical trial set against a thin evidence base, reads as uncritical.
• Endorsing lasers/PRP/injectables on enthusiasm. Vaginal laser, platelet-rich plasma and various injectables are marketed ahead of controlled evidence; presenting them as standard treatment is a critical-appraisal failure.
• Missing the trauma and mood dimensions. Not screening for sexual violence, anxiety, depression and catastrophising — particularly in the South African setting — leaves a major modulator of the pain unaddressed and a safeguarding pathway unopened.

Evidence anchors

• 2015 ISSVD, ISSWSH and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia — Bornstein et al., Obstet Gynecol 2016 (co-published: J Low Genit Tract Dis 2016; J Sex Med 2016)
• Randomized comparison of group CBT, sEMG biofeedback and vestibulectomy — Bergeron et al., Pain 2001
• Surgical and behavioral treatments for vestibulodynia: 2.5-year follow-up — Bergeron et al., Obstet Gynecol 2008
• Oral desipramine and topical lidocaine for vulvodynia: a randomized controlled trial — Foster et al., Obstet Gynecol 2010
• Effect of gabapentin on sexual function in vulvodynia: a randomized, placebo-controlled trial — Bachmann, Brown et al., Am J Obstet Gynecol 2018
• Vulvodynia — an evidence-based literature review and proposed treatment algorithm — De Andres et al., Pain Pract 2016
• 2024 BASHH UK national guideline on the management of vulval conditions — Edwards et al., Int J STD AIDS 2025
• ACOG Committee Opinion No. 673: Persistent Vulvar Pain (2016, with ASCCP) — individualised multidisciplinary management of persistent vulvar pain and vulvodynia.
• South African Medicines Formulary (SAMF) — amitriptyline, gabapentin and topical lignocaine for the pharmacological backbone; NDoH district→regional→tertiary referral structure for the access-stratified plan.